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Abstract
Objective—Few studies have investigated the epidemiology of systemic lupus erythematosus 
(SLE) in American Indian and Alaska Native populations. The objective of this study was to 
determine the prevalence and incidence of SLE in the Indian Health Service (IHS) active clinical 
population in 3 regions of the US.
Methods—For this population-based registry within the IHS, the denominator consisted of 
individuals in the IHS active clinical population in 2007, 2008, and/or 2009 and residing in a 
community in 1 of 3 specified regions. Potential SLE cases were identified based on the presence 
of a diagnostic code for SLE or related disorder in the IHS National Data Warehouse. Detailed 
medical record abstraction was performed for each potential case. The primary case definition was 
documentation in the medical record of ≥4 of the revised American College of Rheumatology 
criteria for the classification of SLE. Prevalence was calculated for 2007, and the mean annual 
incidence was calculated for the years 2007 through 2009.
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Results—The age-adjusted prevalence and incidence of SLE according to the primary definition 
were 178 per 100,000 person-years (95% confidence interval [95% CI] 157–200) and 7.4 per 
100,000 person-years (95% CI 5.1–10.4). Among women, the age-adjusted prevalence was 271, 
and the age-adjusted incidence was 10.4. The prevalence was highest in women ages 50–59 years 
and in the Phoenix Area IHS.
Conclusion—The first population-based lupus registry in the US American Indian and Alaska 
Native population has demonstrated that the prevalence and incidence of SLE are high. Our 
estimates are as high as or higher than the rates reported in the US black population.
Systemic lupus erythematosus (SLE) is an autoimmune disease with many potential 
manifestations and complex classification criteria. Estimates of the overall prevalence of 
SLE in the US have ranged from 15 to 144 per 100,000 (1,2), and the incidence has ranged 
from 1.8 to 23.2 cases per 100,000 per year (1). Many epidemiologic studies have 
documented that SLE is more common in women and in racial/ethnic minority populations, 
especially blacks (1-5). However, studies of the prevalence and incidence of SLE have been 
limited by difficulty validating the classification criteria for SLE at a population level 
without detailed medical record review. Furthermore, most studies have focused on white 
and black populations. Few epidemiologic studies have focused on the prevalence and 
incidence of SLE in other racial/ethnic minority populations.
The prevalence and incidence of SLE in American Indian/Alaska Native populations have 
been estimated in several studies (6,7). In 2 regional studies in the US American Indian/
Alaska Native and Canadian Aboriginal populations (8,9), the age-adjusted prevalence 
ranged from 42 to 112 per 100,000. In both studies, the prevalence of SLE in these 
populations was significantly higher than that in the general population. In addition, the 
Canadian study showed that SLE was more severe in Aboriginal patients and was associated 
with greater mortality (9). A more recent Canadian study using administrative data revealed 
an increased prevalence of SLE that was most pronounced in First Nations women older 
than age 45 years (10). Incidence estimates in the American Indian/Alaska Native 
population have varied, but a study using Indian Health Service (IHS) hospital discharge 
records without case validation showed that the mean annual incidence ranged from 1.2 to 
4.1 per 100,000 person-years in the 1970s and 1980s, with variation by region (7).
In partnership with the Centers for Disease Control and Prevention (CDC), we developed 
the IHS lupus registry. This registry and 4 other CDC-funded registries were designed to 
address the limitations of data on the prevalence and incidence of SLE in racial/ethnic 
minority populations in the US (3). The objective of this population-based registry was to 
determine the prevalence (in 2007) and average annual incidence (from 2007 to 2009) of 
SLE in the IHS active clinical population in 3 regions of the US.
PATIENTS AND METHODS
Study population
This population-based registry was developed as a public health surveillance project within 
the IHS in partnership with the CDC. The protocol was reviewed by the following 
institutional review boards (IRBs) and was determined to be a public health activity and not 
Ferucci et al. Page 2













research: IHS National IRB, Alaska Area IRB, Phoenix Area IRB, and Oklahoma City Area 
IRB. Staff of the CDC IRB previously judged these registries to be public health 
surveillance and not research (3). Permission was obtained from each IHS region or facility 
included in the registry for access to the medical records according to local policies and 
procedures for public health activities and accounting for disclosures.
Any individual included in the IHS active clinical population in 2007, 2008, and/or 2009 
and residing in a community of interest was eligible for inclusion in the registry. Active 
clinical population was defined based on the following criteria: 1) must be alive at the 
beginning of the calendar year; 2) must have 2 or more visits to an IHS-funded clinic in the 
past 3 years, at least 1 of which must be to a core medical clinic (which includes clinics in 
primary care, women’s health, pediatrics, diabetes, and urgent care); and 3) must not be a 
non-Indian beneficiary. The active clinical population is based on the definitions used in 
Government Performance and Results Act (GPRA) reporting and is more restrictive than the 
IHS user population, which captures anyone with at least 1 visit to any IHS-funded clinic 
(including dental and specialty clinics) or at least 1 inpatient stay funded by the IHS in the 
last 3 years and who does not require a visit to a core medical clinic (11). The purpose of 
restricting the population for this project and for GPRA reporting is to include a population 
receiving ongoing medical care at IHS-funded facilities.
Communities of interest selected for inclusion in the registry were those where access to 
rheumatology specialist consultation was available within the IHS system (direct care) at the 
time of development of the registry rather than as an external consultation requiring funding 
from Contract Health Services (contract health care). Across the US, the IHS services are 
administered by 12 Area offices. At the time of the development of this registry, 3 of the 12 
Areas had rheumatologists available for provision of care at IHS facilities (direct care), 
including the Alaska, Phoenix, and Oklahoma City Areas. In these 3 regions, the distribution 
of rheumatology clinics varied, with direct rheumatology care available to all of the active 
clinical population in Alaska and only to residents of certain communities in the other Areas.
Although all 3 Areas had rheumatologists available for direct care at the time of the 
development of the registry, the duration of availability varied by Area, with full direct care 
access since 1976 in Alaska, since 2005 in Phoenix, and not until 2011 (after the time period 
of registry data collection) in the Oklahoma City Area. Communities of interest included in 
the registry are grouped into 3 regions: 1) Alaska (encompassing the entire IHS Alaska 
Area); 2) Phoenix (encompassing the majority of communities in the Phoenix Area); and 3) 
Oklahoma (encompassing 2 Service Units [groupings of communities] in the Oklahoma City 
Area). Separate denominator files were created for each year, based on the active clinical 
population residing in communities of interest in each included region in 2007, 2008, and 
2009.
Case ascertainment
Potential SLE cases were ascertained from the IHS National Data Warehouse (NDW). The 
NDW is a central repository of limited clinical and administrative data needed for 
mandatory reporting by IHS and tribal facilities. Data are transmitted electronically from 
IHS and tribal health care facilities to the NDW. A probabilistic matching strategy is used to 
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assign each individual patient in the national IHS database a unique identifier to be linked 
across all facilities. The NDW contains demographic data (including historic addresses), 
administrative encounter data, and limited clinical data needed for reporting on conditions 
such as diabetes.
The following criteria were applied to each denominator file for each region to select 
potential cases from the NDW: any encounter at any IHS facility from 2006 through the first 
half of 2010 for any of the following International Classification of Diseases, Ninth 
Revision (ICD-9) codes: 710.0, 710.8, 710.9, 695.4, 710.1, and 710.4. These codes include 
codes for SLE, undifferentiated connective tissue disease, discoid lupus, systemic sclerosis, 
and polymyositis, in order to capture a broader range of possible connective tissue disease 
diagnoses that might include SLE. All potential cases were entered into a secure IHS 
database, and demographic information was collected from the NDW to begin populating 
the abstraction database. Medical record abstraction was initiated for all individuals in the 
database.
Field data abstraction
Field medical record abstraction to obtain the detailed information needed for SLE 
classification was performed for all potential cases after they were entered in the database. 
Trained abstractors reviewed medical records, both paper and electronic, for each individual 
at each facility where medical records existed for that individual within our regions of 
inclusion. Data elements included all elements necessary for confirmation of classification 
criteria, date of diagnosis, as well as additional elements related to medication use, other 
potential manifestations of SLE, and complications possibly related to SLE. A standardized 
data dictionary and chart abstraction forms were used, based on those developed by the 
Georgia Lupus Registry (GLR) (4). Abstractors underwent training by the Principal 
Investigator (EDF) that began with an overview of SLE disease manifestations and criteria. 
The training included a detailed review of the definition of all data elements in the data 
dictionary, with examples. Practice charts were used for training. To become certified to 
perform field abstraction, abstractors were required to demonstrate 95% agreement with the 
gold standard for elements constituting the American College of Rheumatology (ACR) 
revised criteria for SLE (12,13) and clinical manifestations and 90% agreement for all other 
elements. After every 100 charts reviewed by an individual abstractor during field medical 
record abstraction, quality assurance audits were performed for 5 charts to ensure agreement 
between abstractors, using the same criteria described above for percent agreement.
Case definitions
Our primary case definition for SLE was documentation of the presence of ≥4 of the 11 
ACR revised criteria for SLE in the medical record. This primary case definition was 
identical to that in the 2 other CDC-funded lupus registries with published results (4,5). We 
used an alternate definition for sensitivity analysis, which included cases meeting the 
primary definition plus those cases with documentation of 3 of 11 ACR criteria in whom the 
final diagnosis of SLE was made by the treating rheumatologist. This alternate definition 
was selected to allow for the clinical judgment of the treating rheumatologist in diagnosing 
this complex disease and account for the potential of missing data in prevalent cases with a 
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long duration of disease. The alternate definition was identical to that used in the GLR (4). 
The ACR criteria were determined according to the standard definitions (12,13), including 
renal disorder (proteinuria >0.5 gm/day or >3+ on at least 2 separate occasions or cellular 
casts present). End-stage renal disease (ESRD) was considered present if chronic dialysis or 
a history of renal transplantation in the medical record was documented by a physician.
Statistical analysis
Prevalence was calculated using the number of cases meeting the primary or alternate 
definition with a date of diagnosis of 2007 or earlier divided by the number of individuals in 
the 2007 denominator, expressed as the rate per 100,000 population. Prevalence was 
calculated overall, by sex, by region (Alaska, Phoenix, Oklahoma), and by age (using the 
following age groups: 0–11 years, 12–19 years, 20–29 years, 30–39 years, 40–49 years, 50–
59 years, 60–69 years, 70–79 years, and 80 years and older). Age-adjusted rates were 
calculated overall and for each sex and region using the 2000 projected US population (14). 
For each proportion, 95% confidence intervals (95% CIs) were calculated (15,16).
Incidence was calculated using the number of cases meeting the primary or alternate 
definition with a date of diagnosis from 2007 to 2009 divided by the number of person-years 
of individuals at risk from 2007 to 2009. Mean annual incidence is reported per 100,000 
person-years. Incidence was calculated overall, by sex, by region, and by age using the same 
age groups as used for prevalence. Age-adjusted rates were calculated overall and for each 
sex and region using the 2000 projected US population (14). For each proportion, 95% CIs 
were calculated. When fewer than 15 cases were available, the incidence was calculated, but 
age-adjusted estimates were not.
The prevalence of individual ACR criteria in prevalent cases meeting our primary case 
definition was calculated overall and by region. Differences between the prevalence of ACR 
criteria by region were analyzed by chi-square or Fisher’s exact test as appropriate. Two-
sided P values less than 0.05 were considered significant. Statistical analyses were 
performed using OpenEpi version 3.01 (17), SAS version 9.3, and Stata.IC version 11.2 for 
Windows.
RESULTS
The flow chart for inclusion in the registry is shown in Figure 1. The denominators for each 
region represent the active clinical population for all communities of interest included in the 
registry in 2007. Potential cases were identified from these denominators for chart 
abstraction, as described above. The number of validated cases according to the primary 
case definition is shown, further subdivided into prevalent cases in 2007 and incident cases 
in 2008–2009. The total number of prevalent cases validated by the primary case definition 
was 285. The cases not validated included miscoded cases, cases with alternate diagnoses, 
and cases with insufficient ACR criteria for classification as SLE. The percentage of cases 
validated was lowest in the Oklahoma region (<10%) but was similar in the Alaska and 
Phoenix regions (35–40%). For all field abstraction quality assurance audits, each abstractor 
passed with 95–96% agreement on key elements and 96–98% overall agreement.
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The prevalence of SLE in 2007 according to the primary and alternate definitions is shown 
in Table 1. The age-adjusted prevalence of SLE in the combined regions according to our 
primary definition was 178 per 100,000 population (95% CI 157–200) and by our broader 
alternate definition was 190 per 100,000 population (95% CI 168–213). The prevalence of 
SLE was significantly higher in women than in men (age-adjusted prevalence by primary 
definition 271 versus 54, with nonoverlapping 95% CIs). The age-adjusted prevalence was 
significantly higher in the Phoenix region for both the primary and alternate definitions (248 
[95% CI 204–297] and 263 [95% CI 219–315], respectively) compared with those in the 
Alaska and Oklahoma regions. The age-specific prevalence rates for the primary definition 
overall and by region and sex are shown in Figure 2. In women, the prevalence was highest 
in a broader age group 50–69 years, while in men, it was highest in those 60–69 years of 
age. The highest prevalence by region, sex, and age group was in women ages 50–59 years 
in the Phoenix region (1,134 [95% CI 830–1,546] by primary definition).
The mean annual incidence of SLE is shown in Table 2. The age-adjusted incidence of SLE 
in the combined regions according to the primary definition was 7.4 per 100,000 person-
years (95% CI 5.1–10.4), and the age-adjusted incidence according to the broader alternate 
definition was 8.6 per 100,000 person-years (95% CI 6.1–11.8). The age-adjusted incidence 
was not calculated for men or for the Oklahoma region due to a small number of cases. 
Differences between remaining regions were not statistically significant. Age-specific 
incidence and prevalence estimates are shown in Table 3 for the combined regions, 
including both men and women. For both definitions, the highest incidence was in the age 
group 40–49 years, and the highest prevalence was in the age group 60–69 years. For the 
285 prevalent cases, the mean ± SD age at diagnosis was 39.2 ± 13.5 years. The mean age at 
diagnosis did not differ significantly by region (P = 0.91). The mean ± SD age at diagnosis 
for incident cases was 45.5 ± 16.2 years, and this did not differ significantly by region (P = 
0.98).
The frequency of the individual ACR criteria in cases in the registry overall and by region is 
shown in Table 4. The presence of antinuclear antibodies (ANAs) was the most common 
criterion (98.2% overall) and did not differ by region. Criteria with significant differences 
between regions included arthritis, immunologic disorder, photosensitivity, renal disorders, 
oral ulcers, and discoid rash. The least frequent criterion was neurologic disorder, which was 
present in 2.8% of cases overall. Renal disorder was present in 39.6% of cases. From 
medical record abstraction, ESRD was noted in 5.6% of prevalent cases, with no statistically 
significant difference by region (P = 0.33).
DISCUSSION
In this population-based lupus registry of American Indian/Alaska Native people within the 
IHS active clinical population in 3 regions of the US, we determined that the prevalence and 
incidence of SLE are high. By our primary case definition, the age-adjusted prevalence of 
SLE in the combined regions was 178 per 100,000 population, with a prevalence of 271 in 
women and 54 in men. Prevalence according to the alternate definition was 190 per 100,000 
for the combined regions, with a prevalence of 289 in women and 57 in men. The age-
adjusted overall incidence was 7.4 per 100,000 person-years according to the primary case 
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definition and 8.6 per 100,000 person-years by the alternate definition. The small number of 
incident cases precluded comparison of age-adjusted incidence rates, but the crude incidence 
was higher in women than in men (8.4 versus 2.7 per 100,000 person-years according to the 
primary definition and 10.1 versus 2.7 per 100,000 person-years by the alternate definition).
The age-adjusted prevalence of SLE in American Indian/Alaska Native women (271 per 
100,000) is similar to that in black women, the population with the highest prevalence of 
SLE described (196 and 186 per 100,000 in the recently published GLR and the Michigan 
Lupus Epidemiology and Surveillance Program [MILES], respectively) (4,5). The age-
adjusted prevalence in American Indian/Alaska Native men was also higher than that in 
black men (54 per 100,000 for American Indian/Alaska Native men, compared with 24 and 
19 per 100,000 in the GLR and MILES, respectively) (4,5). In addition, we observed a 
higher prevalence of SLE compared with previous regional estimates in indigenous 
populations in Southeast Alaska (112 per 100,000) (8) and Manitoba (42 per 100,000) (9). In 
a recent study of the prevalence of SLE among Medicaid-enrolled adults, using 
administrative data, the estimated prevalence in American Indian/Alaska Native people (166 
per 100,000 overall, 213 in women and 49 in men) (2) was comparable with that in our 
registry.
Our estimates of incidence are less precise than our prevalence estimates because of the 
small size of the population included in the IHS registry. However, the age-adjusted 
incidence in the combined regions (7.4 per 100,000 person-years according to the primary 
definition) is higher than most estimates of incidence in the general US population and 
similar to the age-adjusted incidence reported in blacks in the GLR and MILES (8.7 and 7.9 
per 100,000 person-years) (4,5).
The annual incidence of SLE was previously described in the IHS population using hospital 
discharge data from 1971 to 1975 (7). In that older study, incidence was reported by tribe. In 
3 tribes in the northern US, the annual incidence of SLE was increased (16.6–27.1 per 
100,000/year) compared with that in other tribes (0–6.9 per 100,000/year) (6). Those cases 
were validated using the ACR 1971 criteria for the classification of SLE (18). An additional 
study using IHS hospital discharge billing codes from 1980 to 1990 investigated incidence 
by IHS administrative Area (7) and demonstrated the highest incidence of SLE in the 
Aberdeen, Alaska, Billings, and Phoenix Areas (4.1, 3.3, 3.2, and 3.0 per 100,000, 
respectively). We did not include the Aberdeen or Billings Area in this registry. It is no 
longer acceptable to report rates by tribe, without permission from the tribe, but the regions 
included in our registry do not include significant numbers of persons from the tribes noted 
to have the highest incidence of SLE in the study from the 1970s.
We found that the mean age at onset for incident cases was the mid 40s, while the mean age 
at onset for prevalent cases was 39 years. Previous studies have shown a younger age at 
onset in indigenous North American populations (~30 years) (9,19). The age at onset in our 
registry was higher than expected and could possibly be related to the small number of 
incident cases and long duration of disease in prevalent cases.
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Several studies have documented the frequency of individual ACR classification criteria in 
indigenous North American people. In our registry, the 3 most common criteria met by cases 
were ANA positivity (98.2%), hematologic disorder (89.8%), and arthritis (80.4%). Discoid 
rash and neurologic disorder were the least common criteria met (8.4% and 2.8%, 
respectively). A study of rheumatic diseases in Oklahoma tribal populations found that a 
significant proportion of patients with SLE had arthritis (>80%), and that discoid lupus was 
uncommon (20), similar to our findings. The 2 regional studies in Southeast Alaska and 
Manitoba showed a high frequency of ANA positivity (100%) and a high prevalence of 
arthritis (≥90%) (8,9).
Renal disorder was documented in 39.6% of cases in this registry, with ESRD documented 
in 5.6% of cases. Similar to our findings, renal disorder was present in 39% of cases in the 
previous study in Southeast Alaska (8), and cellular casts and proteinuria were present in 
35% and 46% of Aboriginal Manitobans with SLE, respectively (9). The recent data from 
the GLR and MILES showed that renal disorder was present in 36.7% and 40.5% of blacks 
with SLE, respectively (4,5); these percentages are higher than those in whites and are 
similar to the data from the IHS registry. These combined data suggest that renal disease 
may be as common in American Indian/Alaska Native populations with SLE as in black 
patients with SLE. The frequency of renal disease may partially explain the increased 
mortality observed in Aboriginal SLE patients in Manitoba (9). The ESRD data from our 
study are not directly comparable with the data from the GLR and MILES, because we did 
not have access to the United States Renal Data System and based the diagnosis of ESRD on 
medical record review alone. ESRD was noted in 5.6% of patients with SLE in our registry, 
compared with 8.4% of black patients in the GLR (4) and 15.3% of black patients in MILES 
(5). Future studies of SLE in American Indian/Alaska Native populations should further 
investigate ESRD and other measures of disease severity.
There are many possible explanations for the high rates of SLE observed in this registry in 
comparison with other populations and with previous data from American Indian/Alaska 
Native populations. First, our registry captured all documented diagnoses of SLE within the 
IHS system, regardless of the specialty of the provider making the diagnosis. To be included 
in our denominator, individuals were required to have at least 2 visits to an IHS or tribal 
facility in the past 3 years. This criterion could have excluded some healthy individuals who 
do not seek any medical care, leading to higher estimates of prevalence and incidence. 
However, many persons who are eligible for IHS services choose to receive care elsewhere 
because of convenience or other insurance options, and we did not have access to records 
outside the IHS system. Therefore, our denominator was selected to provide the best 
estimates for this population. Second, the previous studies of prevalence in Alaska and 
Canada did perform case validation in a manner similar to that used in our registry but 
included smaller regions and had different methods for case ascertainment (8,9). Third, 
previous studies of incidence in the IHS either used older SLE classification criteria or did 
not validate cases (6,7). Fourth, another possible explanation could be the inclusion of the 
urban location in Phoenix but exclusion of some rural areas. If persons with disease migrate 
to urban areas for medical care, it could lead to an overestimation of prevalence or incidence 
in this region. In addition to migration to urban areas by individuals with disease, it is 
possible that patients with SLE migrate into IHS care as they lose employer-based 
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insurance. However, it is also possible that patients with ESRD migrate out of the IHS given 
that most IHS facilities do not have direct-care nephrologist access or in-house dialysis, and 
quantifying the effects of these possible migrations is difficult. Fifth, SLE is an autoimmune 
disease with strong genetic and environmental associations (21). It is possible that genetic 
risk factors for SLE are overrepresented in the American Indian/Alaska Native population 
(22). Finally, differences in environmental exposures such as sun exposure or tobacco use 
could potentially contribute to the high rates observed in this population and to the regional 
variation in rates.
Our registry has some limitations. First, we included only 3 of the 12 IHS administrative 
Areas. This may limit the generalizability to the entire US American Indian/Alaska Native 
population, especially given the likelihood of variation by region. The rationale for selection 
of these 3 Areas was the likelihood of better data quality in the Areas where specialist access 
was readily available. We believe that the exclusion of the Aberdeen and Billings Areas, 
where previous studies have shown evidence of high rates of SLE, may have led us to 
underestimate the prevalence of SLE. However, the estimates from this project are higher 
than previous estimates for American Indian/Alaska Native populations and as high as those 
reported in black women and men.
Second, we included only select communities within the Phoenix and Oklahoma City Areas, 
which might limit the generalizability of the estimates to the entire administrative Area. 
However, the majority of the Phoenix Area was included, and this limitation is more 
relevant to Oklahoma. Third, this registry was restricted to American Indian/Alaska Native 
people receiving care within the IHS system. This limits the population to members of 
federally recognized tribes who live in proximity to IHS-funded facilities and choose to 
receive care through the IHS. If we had used a broader population denominator of all 
American Indian/Alaska Native people in these regions, our estimates may have been 
slightly lower. However, the differences are not readily quantifiable, because potential cases 
were identified from our denominator, and broadening the denominator could have led to the 
inclusion of additional cases.
Fourth, we used only one data source (the NDW) to identify potential cases. However, the 
NDW was a robust source of demographic and administrative data that helped facilitate the 
creation of the registry. Fifth, the proportion of validated cases was low overall and lower in 
Oklahoma compared with the other regions. We believe the low proportion of validated 
cases in the Alaska and Phoenix regions may be related to the broad set of connective tissue 
disease–associated ICD-9 codes included and the lack of more specific coding definitions 
used in administrative studies, such as the requirement for >1 code or coding by a specialist 
(23). The lower proportion of validated cases in Oklahoma is likely related to the recent 
availability of direct care rheumatology services in Oklahoma IHS. Finally, we captured 
billing codes only from 2006 through the first half of 2010, so it is possible that milder 
prevalent cases could have been missed.
In summary, we observed a high prevalence and incidence of SLE among American Indian/
Alaska Native people in the IHS active clinical population in 3 regions of the US. In 
American Indian/Alaska Native women, the prevalence of SLE is essentially the same as the 
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prevalence in black women in the US, the group in which the prevalence is highest. These 
data support a need for increased awareness of SLE by clinicians in IHS and tribal facilities 
and for research characterizing SLE disease severity and clinical outcomes in American 
Indian/Alaska Native populations.
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Flow diagram for inclusion of potential cases in the population-based systemic lupus 
erythematosus (SLE) registry in the US American Indian and Alaska Native population. The 
denominator for each region represents the active clinical population in 2007 for the 
communities of interest included in the registry. Potential cases in the denominator 
identified as having an International Classification of Diseases, Ninth Revision code 
associated with lupus or other connective tissue disease were flagged for medical record 
abstraction. Potential cases are classified as either not validated (includes miscoded cases, 
alternate diagnoses, and insufficient American College of Rheumatology [ACR] criteria for 
classification as SLE) or validated (documentation in the medical record of ≥4 of the ACR 
classification criteria for SLE). Validated cases are subdivided into prevalent cases (2007) or 
incident cases (2008–2009). Incident cases in 2007 were included in the number of prevalent 
cases in 2007 (*).
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Age-specific prevalence of systemic lupus erythematosus (SLE) based on the primary 
definition (documentation in the medical record of ≥4 of 11 American College of 
Rheumatology classification criteria for SLE) by region and overall, in women (A) and men 
(B).
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Table 1
Prevalence of SLE in 2007 according to the primary and alternate definitions, categorized by sex and region*














Combined regions 211,916 285 134 (120–151) 178 (157–200) 304 144 (128–160) 190 (168–213)
Sex-specific
 Female 116,551 251 215 (190–244) 271 (238–307) 268 230 (204–259) 289 (255–326)
 Male 95,365 34 36 (26–50) 54 (36–77) 36 38 (27–52) 57 (39–81)
Regional
 Alaska 117,964 130 110 (93–131) 149 (124–177) 139 118 (100–139) 159 (133–189)
 Phoenix 70,311 125 178 (149–212) 248 (204–297) 133 189 (160–224)) 263 (219–315)
 Oklahoma 23,641 30 127 (89–179) 138 (93–200) 32 135 (96–191) 147 (100–210)
*
Rates are per 100,000 population. Age-adjusted rates were calculated using the 2000 projected US population and 10-year age groups (14). The 
primary definition is documentation in the medical record of ≥4 of 11 American College of Rheumatology (ACR) classification criteria for 
systemic lupus erythematosus (SLE). The alternate definition is the primary definition or documentation of ≥3 ACR criteria and a final diagnosis of 
SLE made by the treating rheumatologist. 95% CI = 95% confidence interval.
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Table 2
Mean annual incidence of SLE from 2007 through 2009 according to the primary and alternate definitions, 
categorized by sex and region*















Combined regions 649,302 38 5.9 (4.2–8.0) 7.4 (5.1–10.4) 44 6.8 (5.0–9.0) 8.6 (6.1–11.8)
Sex-specific
 Female 357,137 30 8.4 (5.8–11.8) 10.4 (6.6–14.6) 36 10.1 (7.2–13.8) 12.1 (8.3–17.1)
 Male 292,165 8 2.7 (1.3–5.2) – 8 2.7 (1.3–5.2) –
Regional
 Alaska 357,419 17 4.8 (2.9–7.5) 6.1 (3.4–10.2) 20 5.6 (3.5–8.5) 7.2 (4.2–11.5)
 Phoenix 221,770 18 8.1 (5.0–12.6) 10.7 (6.2–17.5) 21 9.5 (6.0–14.2) 12.7 (7.6–20.1)
 Oklahoma 70,113 3 4.3 (1.1–11.7) – 3 4.3 (1.1–11.7) –
*
Rates are per 100,0000 person-years. Age-adjusted rates were calculated using the 2000 projected US population and 10-year age groups (14). 
The primary definition is documentation in the medical record of ≥4 of 11 American College of Rheumatology (ACR) classification criteria for 
systemic lupus erythematosus (SLE). The alternate definition is the primary definition or documentation of ≥3 ACR criteria and a final diagnosis of 
SLE made by the treating rheumatologist. 95% CI = 95% confidence interval.
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Table 3
Overall age-specific incidence of SLE from 2007 to 2009 and age-specific prevalence of SLE in 2007 
according to the primary and alternate definitions*
Incidence Prevalence



















0–11 0 0.0 (0.0–2.1) 0 0.0 (0.0–2.1) 0 0.0 (0.0–6.5) 0 0.0 (0.0–6.5)
12–19 2 2.0 (0.6–7.4) 2 2.0 (0.6–7.4) 3 9.1 (3.1–26.7) 3 9.1 (3.1–26.7)
20–29 6 5.8 (2.6–12.6) 8 7.7 (3.9–15.2) 21 63.1 (41.2–96.4) 24 72.1 (48.4–107.2)
30–39 5 6.7 (2.9–15.8) 5 6.7 (2.9–15.8) 42 174.7 (129.3–236.1) 44 183.0 (136.4–248.0)
40–49 13 16.5 (9.6–28.2) 16 20.3 (12.5–32.9) 67 253.6 (199.7–321.9) 73 276.3 (219.8–347.2)
50–59 7 11.9 (5.8–24.5) 7 11.9 (5.8–24.5) 89 471.8 (383.6–580.1) 93 493.0 (402.6–603.5)
60–69 3 9.5 (3.2–27.9) 3 9.5 (3.2–27.9) 53 526.2 (402.5–687.5) 55 546.0 (419.8–710.0)
70–79 1 6.0 (1.1–34.2) 2 12.1 (3.3–44.1) 8 148.8 (75.4–293.4) 10 186.0 (101.1–342.1)
80+ 1 15.4 (2.7–87.0) 1 15.4 (2.7–87.0) 2 94.9 (26.0–345.4) 2 94.9 (26.0–345.4)
*
Rates are per 100,0000 person-years. The primary definition is documentation in the medical record of ≥4 of the American College of 
Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE). The alternate definition is the primary definition or 
documentation of ≥3 ACR criteria and a final diagnosis of SLE made by the treating rheumatologist. 95% CI = 95% confidence interval.
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Table 4
Frequency of the individual ACR criteria for the classification of systemic lupus erythematosus among 285 










Presence of ANAs 98.2 99.2 97.6 96.7
Hematologic disorder 89.8 90.0 90.4 86.7
Arthritis† 80.4 71.5 94.4 60.0
Immunologic disorder† 60.7 71.5 51.2 53.3
Photosensitivity† 53.0 56.9 55.20 26.7
Serositis 48.1 44.6 54.4 36.7
Renal disorder† 39.6 51.5 28.0 36.7
 End-stage renal disease‡ 5.6 6.9 5.6 0
Oral ulcers† 35.1 30.8 44.8 13.3
Malar rash 31.6 27.7 35.2 33.3
Discoid rash† 8.4 3.1 15.2 3.3
Neurologic disorder 2.8 4.6 0.8 3.3
*
The primary definition is documentation in the medical record of ≥4 of the American College of Rheumatology (ACR) classification criteria for 
systemic lupus erythematosus. Values are the percent. ANAs = antinuclear antibodies.
†
Significant (P < 0.01) differences between regions.
‡
Defined by abstraction only.
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